摘要
黄酮类化合物是重要的中药有效成分,主要有抗肝损伤、抗氧化、解痉、雌激素样等作用,该类化合物对心脑血管的作用明显。巨噬细胞源性泡沫细胞是动脉粥样硬化(AS)发生过程中的关键介质,在斑块中,血清脂质、血清脂蛋白以及各种促炎或抗炎刺激因子、趋化因子和小的生物活性分子均可显著影响巨噬细胞表型,诱导其向更强的促炎或抗炎特性转变。研究发现部分黄酮类化合物可通过不同的通路及机制作用于巨噬细胞,发挥不同程度的抗动脉粥样硬化作用,包括促进巨噬细胞胆固醇流出、抗巨噬细胞泡沫化、抑制炎性因子分泌、抗氧化修饰低密度脂蛋白(ox-LDL)诱导的巨噬细胞凋亡,相关的基因调控包括ATP结合盒转运蛋白A1(ABCA1)、ATP结合盒转运蛋白G1(ABCG1)、Toll样受体(TLR)、清道夫受体(SR)。该文就近年来黄酮类化合物对通过巨噬细胞介导的抗动脉粥样硬化作用的研究进展做一综述,以期为AS性心脑血管疾病提供新治疗策略,为相关天然药物的利用及新产品设计提供研究思路与开发方向。
Flavonoids are important active ingredients of traditional Chinese medicine,mainly with cardiovascular,anti-liver injury,antioxidant,antispasmodic,and estrogen-like effects.These compounds have obvious effects on the cardiovascular and cerebrovascular diseases.Macrophage-derived foam cells are the key medium in the process of atherosclerosis(AS).In plaque,allserum lipids,serum lipoproteins,and various pro-or anti-inflammatory stimulating factors,chemokines,and small bioactive molecules can significantly affect the macrophage phenotype and induce stronger pro-inflammatory or anti-inflammatory properties.Studies have shown that some flavonoids can be used for macrophages through different pathways and mechanisms,playing an anti-atherosclerosis effect to different degrees,including promotion of cholesterol efflux from macrophages,anti-foaming of macrophages,inhibition of secretion of inflammatory factors,and antioxidant modified low density lipoprotein(ox-LDL)-induced apoptosis of macrophages.Related gene regulation inclu-ded ATP-binding cassette transporter A1(ABCA1),ATP-binding cassette transporter G1(ABCG1),Toll-like receptor(TLR),and scavenger receptor(SR).In this article,we would review the recent research progress of flavonoids on anti-atherosclerosis effect me-diated by macrophage.It is expected to provide new treatment strategies for AS-related cardiovascular and cerebrovascular diseases,and provide research ideas and development directions for the use of related natural medicines and design of new products.
作者
李鸿
白鹭
覃琴
冯柏林
张良
韦飞燕
杨秀芬
LI Hong;BAI Lu;QIN Qin;FENG Bo-lin;ZHANG Liang;WEI Fei-yan;YANG Xiu-fen(Department of Pharmacology,School of Pharmacy,Guangxi University of Chinese Medicine,Nanning 530200,China;Guangxi Key Laboratory of Zhuang arul Yao Ethnic Medicine,Nanning 530200,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第12期2827-2834,共8页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81260652,81060353,81960698)
广西自然科学基金重点项目(2015GXNSFDA139023)
第八批广西特聘专家项目(桂人才通字[2019]13号)
广西壮瑶药重点实验室项目(桂科基字[2014]32号)
壮瑶药协同创新中心项目(桂教科研[2013]20号)
广西重点学科壮药学项目(桂教科研[2013]16号)
广西中医药大学广西一流学科建设开放课题(2019XK113,2019XK122)。
